Thank you, Marr Family

When we began our partnership a decade ago, disease-modifying therapies for Alzheimer’s disease seemed a distant dream. Now that we have approved therapies for early symptomatic Alzheimer’s, the field is increasingly looking toward even earlier intervention, specifically targeting people with evidence of Alzheimer’s in their brain but before clinical symptoms are clearly evident. Due to your generosity and commitment to advancing Alzheimer’s research, we are now leading clinical trials with those recently approved treatments in people who do not yet have symptoms and are as young as 55.

Below are two special videos from our investigators, Tracy Young-Pearse, PhD, and Rachel Buckley, PhD, whom you have supported this past year. Fueled by your generosity, their groundbreaking work is paving the way toward better understanding and, ultimately, treating this complex disease.

Your dedication has been truly inspiring, and the partnership from your family and many others through the Marr Fund allows us to continue to make major progress. And hopefully, one day soon, we will be able to completely prevent Alzheimer’s disease from developing in the brain.

With deepest gratitude,

Reisa A. Sperling, MD, MMSc
Director, Center for Alzheimer Research and Treatment
Remondi Family Distinguished Chair in Neurology
Co-leader, Davis Alzheimer Prevention Program

To learn more about the Josephine and John Marr Alzheimer’s Research Fund, please contact Ginny Fuller at vgfuller@bwh.harvard.edu or 617 510 9869.